1. Search Result
Search Result
Results for "

inhibit lipid accumulation

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Biochemical Assay Reagents

10

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N8466

    Reactive Oxygen Species Metabolic Disease
    (-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .
    (-)-Lyoniresinol 9'-O-glucoside
  • HY-N12440

    Others Others
    Sarmenoside II is a flavonol glycoside with activity that inhibits lipid accumulation. Sarmenoside II inhibits albumin-oleate-induced lipid accumulation in HepG2 cells by approximately 30% at 100 μM.
    Sarmenoside II
  • HY-N10063

    Others Metabolic Disease
    Penispidin A inhibits hepatic lipid accumulation in HepG2 cells.
    Penispidin A
  • HY-124417

    Others Metabolic Disease
    SBI-477 (compound 41) analog inhibits intracellular lipid accumulation, increase celluar glucose uptake .
    SBI-477 analog
  • HY-N10428

    Others Metabolic Disease
    Ganoapplanoid F, a highly oxygenated lanostane triterpenoid from Ganoderma applanatum, inhibits lipid accumulation in adipocytes. Ganoapplanoid F can be used for the research of obesity .
    Ganoapplanoid F
  • HY-137996

    Akt mTOR Metabolic Disease
    Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .
    Dehydrovomifoliol
  • HY-139369

    Reactive Oxygen Species Cancer
    QD394 is a reactive oxygen species (ROS) inducer that can induce lipid peroxidation, increase intracellular ROS accumulation, inhibit STAT3 phosphorylation, and induce ferroptosis .
    QD394
  • HY-131999

    Others Metabolic Disease
    3,4,5-Trihydroxycinnamic acid decyl ester is an excellent inhibitor of lipid absorption and accumulation, with anti-obesity properties. 3,4,5-Trihydroxycinnamic acid decyl ester is a pancreatic lipase inhibitor, with an EC50 of approximately 0.9 μM .
    3,4,5-Trihydroxycinnamic acid decyl ester
  • HY-128075

    Others Cancer
    Acifluorfen, a protoporphyrinogen oxidase (PROTOX) inhibitor herbicide, promotes the accumulation of protoporphyrin IX (PPIX), and induces tumors in the rodent liver. Acifluorfen causes strong photooxidative destruction of pigments and lipids in sensitive plant species .
    Acifluorfen
  • HY-119248

    MK-0767

    PPAR Metabolic Disease
    KRP-297 is a PPARα and PPARγ agonist potentially for the research of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.
    KRP-297
  • HY-156010

    PPAR Metabolic Disease
    PPARγ-IN-2 (Compound 5a) is a PPARγ inhibitor. PPARγ-IN-2 inhibits TG accumulation in 3T3-L1 preadipocytes (EC50: 0.106 μM). PPARγ-IN-2 inhibits high-cholesterol diet (HFC)-induced obesity and related metabolic syndrome, and reduces lipid accumulation in adipose tissue .
    PPARγ-IN-2
  • HY-N6707
    Triacsin C
    3 Publications Verification

    WS 1228A; FR 900190

    Parasite Infection
    Triacsin C (WS 1228A), a natural intracellular long-chain acyl-CoA synthetases (ACSL) inhibitor, is from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity . Triacsin C is found to be highly effective against rotavirus replication .
    Triacsin C
  • HY-133707

    Endogenous Metabolite Metabolic Disease
    β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .
    β-Muricholic acid
  • HY-139230

    Cannabinoid Receptor PPAR Metabolic Disease
    OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) .
    OLHHA
  • HY-50683
    JNJ-38877605
    3 Publications Verification

    c-Met/HGFR Metabolic Disease Cancer
    JNJ-38877605 is an orally active ATP-competitive inhibitor of c-Met with an IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases . JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach .
    JNJ-38877605
  • HY-B0600

    AFP-168; MK2452

    Others Others
    Tafluprost (AFP-168) is an anti-glaucoma prostaglandin (PG) analog. Tafluprost can inhibit the apoptosis of retinal ganglion cells (RGCs) and rat RGCs cells. Tafluprost promotes axon regeneration by regulating Zn 2+-mTORpathway, inhibits intracellular lipid accumulation in human preorbital adipocytes. Tafluprost can be used in the study of optic nerve injury in glaucoma .
    Tafluprost
  • HY-148918

    β-catenin Wnt Cancer
    E722-2648 is a potent β-catenin/BCL9 complex inhibitor. E722-2648 specifically inhibits β-catenin/BCL9 complex formation and Wnt activity. E722-2648 disrupts cholesterol homeostasis via increased cholesterol esterification and lipid droplet accumulation. E722-2648 has antitumor activity .
    E722-2648
  • HY-133180

    Wnt β-catenin Metabolic Disease
    YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism .
    YW1128
  • HY-129143

    Dp3‐Sam chloride

    Others Metabolic Disease Inflammation/Immunology
    Delphinidin-3-sambubioside (Dp3‐Sam) chloride is an anthocyanin that has orally active anti-inflammatory activity. Delphinidin-3-sambubioside chloride inhibits LPS-induced inflammatory factors release. Delphinidin-3-sambubioside chloride also alleviates hepatic lipid accumulation in HFD rats. Delphinidin-3-sambubioside chloride can be isolated from Hibiscus sabdariffa L. .
    Delphinidin-3-sambubioside chloride
  • HY-146683

    Aldehyde Dehydrogenase (ALDH) Apoptosis Cancer
    KS106 is a potent ALDH inhibitor with IC50s of 334, 2137, 360 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS106 shows antiproliferative and anticancer effects with low low toxic.KS106 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS106 induces apoptosis and cell cycle arrest at the G2/M phase .
    KS106
  • HY-146682

    Aldehyde Dehydrogenase (ALDH) Apoptosis Cancer
    KS100 is a potent ALDH inhibitor with IC50s of 230, 1542, 193 nM for ALDH1A1, ALDH2, and ALDH3A1, respectively. KS100 shows antiproliferative and anticancer effects with low low toxic. KS100 significantly increases ROS activity, lipid peroxidation and toxic aldehyde accumulation. KS10600 induces apoptosis and cell cycle arrest at the G2/M phase .
    KS100
  • HY-W005130

    NF-κB Metabolic Disease
    2,4,6-Trihydroxybenzaldehyde is an orally active NF-ĸB inhibitor. 2,4,6-Trihydroxybenzaldehyde shows anti-tumor activity, anti-cancer cell proliferative activity and anti-obesity activity .
    2,4,6-Trihydroxybenzaldehyde
  • HY-115319
    CP-24879 hydrochloride
    1 Publications Verification

    Ferroptosis Inflammation/Immunology
    CP-24879 (hydrochloride) is a potent, selective and combined delta5D/delta6D inhibitor. CP-24879 (hydrochloride) can significantly reduce intracellular lipid accumulation and inflammatory injury in hepatocytes. CP-24879 (hydrochloride) exhibits superior antisteatotic and anti-inflammatory actions in fat-1 and ω-3-treated hepatocytes, and can be used for non-alcoholic steatohepatitis research .
    CP-24879 hydrochloride
  • HY-W127409

    Biochemical Assay Reagents Others
    1,2-Dimyristoyl-rac-glycerol (C14:0) is a carboxylic acid ester, glycerolipid and diglyceride with an additional myristoyl group that facilitates interactions between proteins and lipids. Can be used as detergent or reagent. It plays a role in cell biology experiments involving the metabolism and metabolic pathways of glycerolipids. As a diglyceride, this substance consists of two fatty acid chains covalently bonded in the 1,2-form to a glycerol molecule. The diglyceride (DAG) study investigated the process by which DAG is depleted to inhibit fat accumulation. Reagent grade, for research use only.
    1,2-Dimyristoyl-rac-glycerol
  • HY-N11507

    TKV

    PPAR Metabolic Disease
    Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders .
    Tibesaikosaponin V
  • HY-B0852

    Cytochrome P450 Fungal Apoptosis Infection
    Tebuconazole is an orally active agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicans CYP51 (CaCYP51) and truncated Homo sapiens CYP51 (Δ60HsCYP51), respectively. Tebuconazole induces lipid accumulation and oxidative stress in HepG2 Cells. Tebuconazole decreases MAC-T cells viability and proliferation, induces ER-stress-mediated apoptosis and increases oxidative stress levels in MAC-T cells .
    Tebuconazole
  • HY-117049

    CDK DYRK Neurological Disease
    Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3 (IC50s = 0.04, 0.035, 0.015, and 4.5 µM, respectively) . Leucettine L41 prevents lipid peroxidation and the accumulation of reactive oxygen species (ROS) induced by Aβ25-35 in the hippocampus in a mouse model of Alzheimer’s disease-like toxicity. Leucettine L41 also prevents memory deficits induced by Aβ25-35 in the same model .
    Leucettine L41
  • HY-B0852R

    Cytochrome P450 Fungal Apoptosis Infection
    Tebuconazole (Standard) is the analytical standard of Tebuconazole. This product is intended for research and analytical applications. Tebuconazole is an orally active agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicans CYP51 (CaCYP51) and truncated Homo sapiens CYP51 (Δ60HsCYP51), respectively. Tebuconazole induces lipid accumulation and oxidative stress in HepG2 Cells. Tebuconazole decreases MAC-T cells viability and proliferation, induces ER-stress-mediated apoptosis and increases oxidative stress levels in MAC-T cells .
    Tebuconazole (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: